Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New breast cancer marker "better than CEA":

This article was originally published in Clinica

Executive Summary

The serum concentration of a fragment of cytokeratin 19 (CYFRA 21-1) may be one of the most reliable tumour markers for breast cancer recurrence. Researchers from the Osaka City University Hospital, Japan, report in Cancer (September 15th) that CYFRA 21-1 was elevated in patients with later stage and recurrent breast tumours, but not in patients with other breast disorders. In a comparison with other breast cancer markers, CYFRA 21-1's sensitivity was as high as that of CA 15-3 and better than that of carcinoembryonic antigen.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel